Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta-analysis of randomized controlled trials
Abstract
The aim of this study was to compare more conclusively the efficacy and safety of moxifloxacin, a new respiratory fluoroquinolone antibiotic with levofloxacin therapy which has been reported to possess good efficacy for community acquired pneumonia (CAP) in hospitalized elderly patient. The entire patients were mild to moderate by CAP. All the trials administered intravenously moxifloxacin (400 mg daily) and intravenously levofloxacin (200500 mg daily) for 7-14 days. Clinical response during therapy was between days 3 and 5 after the start of therapy. A meta-analysis of randomized controlled trials (RCTs, identified in CNKI, PubMeD, Embase, Google) were performed. Eight RCTs involving 1310 patients were included in metaanalysis. Two reviewers independently extracted data from published trials that compared fluoroquinolones. A meta-analysis was performed with the clinical outcomes of moxifloxacin and levofloxacin. Moxifloxacin monotherapy was associated with better therapeutic effect [(OR=1.63, 95%CI 1.01-2.63) and similar adverse effect (OR=1.12, 95%CI 0.81-1.55)] compared with levofloxacin therapy for CAP. Moxifloxacin has better therapeutic effects with comparable adverse events compared to levofloxacin.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,310 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.